Qin Jing, Lu Hongyang
Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (Lung and Esophagus), Zhejiang Cancer Hospital, Hangzhou 310022, People's Republic of China.
Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, People's Republic of China.
Onco Targets Ther. 2018 Jun 19;11:3505-3511. doi: 10.2147/OTT.S159057. eCollection 2018.
Currently, studies assessing combined small-cell lung carcinoma (C-SCLC) are relatively scarce and limited. Indeed the clinicopathological features, treatment, and prognosis of patients with C-SCLC have not been fully determined. The incidence of C-SCLC ranges from 5%-28% in different studies, which is related to the specimen types used. The clinical features of C-SCLC are characterized by the higher proportion of peripheral locations, earlier stage, and more opportunity to experience surgery. Surgery is more important for earlier stage C-SCLC. There have been no recent changes in the chemotherapy of C-SCLC, which is recommended by the treatment guidelines for SCLC, neither showing survival benefit from the 3-agent regimen. Meanwhile, the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in EGFR-mutated C-SCLC patients remains inconclusive. This review focuses on clinical and pathologic features, prognostic factors, and optimized treatment model in C-SCLC.
目前，评估合并小细胞肺癌（C-SCLC）的研究相对较少且有限。事实上，C-SCLC患者的临床病理特征、治疗方法和预后尚未完全明确。在不同研究中，C-SCLC的发病率在5%至28%之间，这与所使用的标本类型有关。C-SCLC的临床特征表现为外周部位比例较高、分期较早以及有更多接受手术的机会。手术对早期C-SCLC更为重要。C-SCLC的化疗方案近期没有变化，遵循小细胞肺癌治疗指南推荐，三药联合方案也未显示出生存获益。同时，表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）在EGFR突变的C-SCLC患者中的疗效仍不明确。本综述聚焦于C-SCLC的临床和病理特征、预后因素以及优化治疗模式。
